Base Metals Investing Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
Base Metals Investing Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
Base Metals Investing Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
Base Metals Investing Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
80 Mile PLC Secures 3 Strategic MOUs with Fortune 500 Energy Group, Ludoil, and JEnergy and moves to 100% of Ferrandina Biofuels Plant
Cotec Purchases Commercial Scale Salter Cyclone Multi-Gravity-Separator Unit to be Located at Corem Québec, Canada